High Yields, Low Production Cost Give The Flowr Corporation

New Post Public Reply Private Reply Replies (0) Message Board
NetworkNewsWire
1,265
High Yields, Low Production Cost Give The Flowr Corporation (TSX.V: FLWR) (OTC: FLWPF) Competitive Advantage in Cannabis Market

- The Flowr Corporation anticipates maximizing yield even further, lowering production costs to C$2.05 per gram in 2019
- Company seeking strategic partnerships to ensure solid distribution channels and opportunities to advance cultivation techniques
- Cannabis supply expected to surpass demand, giving competitive advantages to companies with high yields and low production costs

Canadian cannabis product manufacturer The Flowr Corporation (TSX.V: FLWR) (OTC: FLWPF) has designed and built 17 cultivation facilities to date, relying on innovative processes to ensure high yields and low production costs. This methodology could give Flowr a competitive advantage moving forward as anticipated changes occur in the cannabis sector.

A vertically integrated company, The Flowr Corporation produces premium cannabis products and currently operates under three producer licenses issued by Health Canada. Under the guidance of its knowledgeable and experienced executive team, the company has established a flagship Kelowna campus — a facility that’s considered to be one of the most advanced in terms of cannabis cultivation worldwide.

Such assets could provide Flowr with a significant advantage over the competition in the next few years. According to industry analysis, an upcoming supply glut is anticipated in the cannabis sector. Supply is on pace to surpass demand for the product by 2020, a market development that will favor producers capable of ensuring high yields and cost efficiency (http://nnw.fm/sK1DM).

The Flowr Corporation differentiates itself from the competition through the exceptional yield per square foot at its production facilities. As the supply continues to increase, companies will be forced to reduce their prices in order to remain competitive. Flowr has already reached a price point that may be difficult for others to surpass.

To increase its competitiveness even further, Flowr is currently working on optimizing its yield. Company co-founder and Chairman Steve Klein noted that yield is the most important performance indicator in the industry. Higher yields reduce production costs, and, in 2019, Flowr anticipates reaching a cost of C$2.05 per gram.

According to an article published by investment advice website The Motley Fool, Flowr beats most Canadian producers when it comes to crop yields. The company’s cost per gram announced for 2019 is lower than what large marijuana producers such as Canopy Growth Corp. (TSX: WEED) (NYSE: CGC) and Tilray Inc. (NASDAQ: TLRY) are capable of offering.

Flowr has also been working to ensure a solid distribution network via partnerships with reputable industry representatives.

Earlier this month, Flowr and Shoppers Drug Mart announced a multiyear deal for the supply of medical cannabis for the Shoppers online store (http://nnw.fm/VxSg5). Shoppers Drug Mart is Canada’s largest retail pharmacy chain, with 1,300 locations from coast to coast.

The partnership will provide patients with premium medicinal cannabis, according to Flowr co-CEO Tom Flow. Strict processes and state-of-the-art growing facilities enable Flowr to provide patients with high-quality product and consistent benefits.

Flowr focuses on premium and ultra-premium production. As a result, the company anticipates appealing even more to an exclusive group of customers. In addition, this adherence to strict industry standards resulted in a research and development partnership with Scotts Miracle-Gro (NYSE: SMG) subsidiary Hawthorne Gardening. In October 2018, the two companies broke ground on North America’s first research and development facility dedicated to advancing cannabis cultivation techniques (http://nnw.fm/xCi1Q).

For more information, visit the company’s website at www.Flowr.ca

Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Scroll down for more posts ▼

Top 10 Most Recent News Articles

First-Time Homeowners: Unseen Pitfalls of Insurance

Updated Category News Views 2

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Continue Reading
PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

Updated Category News Views 4

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Continue Reading
GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 5

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading
Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 3

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading
MRI Surveillance Gains Ground in Lung Cancer Care

Updated Category News Views 5

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Continue Reading
PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 6

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading
UWM Faces Class Action Deadline: Key Insights for Investors

Updated Category News Views 2

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Continue Reading
Ris-Rez May Set New Standard in Relapsed SCLC

Updated Category News Views 6

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Continue Reading
Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 5

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading
Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 7

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading

Top 5 Most Recently Viewed Articles

Black Diamond Group Achieves Key Milestones in Q3 2024

Updated Category News Views 251

Black Diamond Group Reports Strong Q3 2024 Performance Black Diamond Group Limited, recognized for its space rental and workforce accommodation solutions, recently reported its operating and financial results for the third quarter of 2024. The company has shown remarkable resilience with a strong foundation, enabling it to adapt to changing market dynamics and maintain...

Continue Reading
Potential Unicredit and Commerzbank Merger Promises Stakeholder Gains

Updated Category News Views 194

Unicredit and Commerzbank Merger: A Possible Game Changer The potential merger between Italy's Unicredit and Germany's Commerzbank has certainly caught the attention of the banking industry. In a recent interview with Handelsblatt, Unicredit's CEO, Andrea Orcel, shared his perspective, suggesting that this merger could bring significant advantages for all parties...

Continue Reading
Future Trends and Growth of Wearable Cardiac Devices in Healthcare

Updated Category News Views 100

Unlocking the Future of Wearable Cardiac Devices In the rapidly evolving landscape of healthcare technology, wearable cardiac devices have emerged as game-changers. These devices, which include smartwatches and ECG patches, are not just sophisticated gadgets; they represent the forefront of health monitoring. Predictions suggest that the global market for wearable cardiac...

Continue Reading
Pivotal Research Starts Coverage of Alphabet and Meta Stocks

Updated Category News Views 75

Pivotal Research Initiates Coverage of Alphabet and Meta Pivotal Research Group has recently begun coverage of Alphabet Inc. (NASDAQ: GOOGL), renowned for being the parent company of Google, assigning it a Buy rating. This rating comes from the assessment of Alphabet's strong competitive stance and promising growth trajectory in cloud computing and artificial intelligence...

Continue Reading
Innovative Belt Design Enhances Comfort and Style for All

Updated Category News Views 130

Revolutionizing Belt Design for Enhanced Functionality Inventors are always looking for ways to improve everyday items, and the MAGNET BELT is a prime example of innovative thinking. One inventor recognized the frustrations that come with traditional belt designs and sought a solution. "I envisioned a better method to secure the end portion of a belt to stop it from...

Continue Reading